Marker Driven Selection of Patients for Prostate Biopsy and Management

Prostate Cancer Clinical Trial

— MDSelect  

Official title:

Marker Driven Selection of Patients for Prostate Biopsy and Management: The University of Miami MDSelect Protocol

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04240327
• Other study ID #: 20190864
• Secondary ID: U01CA239141-01A1
• Status: Recruiting
• Start date: June 29, 2020
• Est. completion date: June 1, 2025

Study information

• Verified date: April 2024
• Source: University of Miami
• Contact: Elena M Cortizas, MS
• Phone: 305-243-6438
• Email: ecortizas[@]med.miami.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective at detecting prostate cancer than standard of care interpretation of mpMRI with the Prostate Imaging Reporting and Data System (PIRADS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 1, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male participant, aged 40-85 years.

2. In good general health as evidenced by medical history.

3. Referred for a biopsy of the prostate for evaluation of prostate cancer due to elevated or increasing prostate-specific antigen (PSA) or an abnormal digital rectal exam (DRE).

4. Participant must agree to forego testosterone supplementation during the duration of the study due to unknown impacts on prostate cancer biomarkers.

Exclusion Criteria:

1. Previous or current history of prostate cancer or treatment for prostate cancer.

2. Previous history of pelvic radiation.

3. Known allergic reactions to MRI contrast or inability to undergo MRI due to renal toxicity.

4. Inability to undergo blood draw or biopsy of the prostate as per protocol.

5. Prior MRI guided biopsy of the prostate for prostate cancer evaluation.

6. Previous prostate biopsy or prostate procedure within 6 months of enrollment within the trial.

7. Standard contraindications to MRI, such as allergies to contrast die, renal toxicity, ferromagnetic metal in body/eye, pacemaker, defibrillator, other mechanical device, or extreme claustrophobia (medication with anti-anxiety agents, such as Ativan, may be attempted) will prevent eligibility and will be applied for all protocol-related MRIs.

8. Patients with impaired decision-making capacity.

Related Conditions & MeSH terms

• Elevated PSA
• Prostate Cancer
• Prostatic Neoplasms
• PSA

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Negative Predictive Value (NPV) for ruling out GG2+ prostate cancer via Habitat Risk Score (HRS) MRI Interpretation software combined with a panel of blood and urine biomarkers, versus via standard of care (SoC) MRI interpretation with PIRADS v2.	The investigators will assess whether automated quantitative HRS MRI interpretation software combined with a panel of blood and urine biomarkers incrementally improves the negative predictive value for ruling out GG2+ cancer on prostate biopsy by 30% or more above standard of care (SoC) MRI interpretation with PIRADS v2.	Up to 24 months
Secondary	NPV for ruling out GG2+ prostate cancer via HRS MRI Interpretation software versus via SoC MRI interpretation with PIRADS v2	The investigators will assess whether automated quantitative HRS MRI interpretation software can incrementally improve the negative predictive value (NPV) for ruling out GG2+ cancer on prostate biopsy by 20% or more above SoC MRI interpretation with PIRADS v2.	Up to 24 months
Secondary	NPV for ruling out GG2+ prostate cancer by a panel of blood and urine biomarkers versus via SoC MRI interpretation with PIRADS v2	The investigators will assess whether a panel of blood and urine biomarkers can incrementally improve the negative predictive value (NPV) for ruling out GG2+ cancer on prostate biopsy by 10% or more above SoC MRI interpretation with PIRADS v2.	Up to 24 months
Secondary	NPV for ruling out clinically significant prostate cancer via HRS MRI interpretation software combined with a panel of blood and urine biomarkers versus via SoC MRI interpretation with PIRADS v2	The investigators will assess whether automated quantitative HRS MRI interpretation software combined with a panel of blood and urine biomarkers incrementally improves the negative predictive value for ruling out clinically significant prostate cancer (defined as any GG2+ cancer OR 50% or more cores of GG1 cancer) on prostate biopsy by 30% or more above standard of care MRI interpretation with PIRADS v2	Up to 24 months